Abstract: The present invention is a microbially inert, optimized carrier medium for fresh Fecal Microbiota Transplantation samples, intended for same-day transplantation, in which the carrier material is gastrointestinally active while remaining predominantly microbially inert. The key active agent in the present optimized collection and transplantation medium is polyethylene glycol, and in one embodiment of the invention the 1,000,000 to 10,000,000 grams per mole molecular weight of the polyethylene glycol provides a useful high viscosity to the present collection/carrier medium.

Abstract: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Abstract: An oral supplement composition and method of making and using it, in which a combination of fourteen different specialized mushroom species, each of which has its own unique immunomodulatory properties, demonstrate enhancement of the immune system. When taken together, the combination of mushroom species exert a potentiated, synergistic effect that enhances immune function greater than the sum of each mushroom species' immunoenhancing influence. The oral supplement can be prepared into a variety of dosage forms, such as capsules, caplets, tablets, pills, dispersions, suspensions, solution, powders, teas, or syrup concentrates, and can be packaged in bottles or other packaging for sale.

Abstract: An oral supplement composition and method of making and using it, in which a combination of fourteen different specialized mushroom species, each of which has its own unique immunomodulatory properties, demonstrate enhancement of the immune system. When taken together, the combination of mushroom species exert a potentiated, synergistic effect that enhances immune function greater than the sum of each mushroom species' immunoenhancing influence. The oral supplement can be prepared into a variety of dosage forms, such as capsules, caplets, tablets, pills, dispersions, suspensions, solution, powders, teas, or syrup concentrates, and can be packaged in bottles or other packaging for sale.

Abstract: A noningestible separation barrier having one or more pores or micropores (of one or more diameters) therein, with the pores or micropores being initially plugged with one or more materials selected for its/their solubility and/or integrity characteristics relative to certain environmental conditions. Ordinarily, the pores or micropores of the noningestible separation barrier are initially filled with at least one material having greater erodibility, under a given environmental condition, than the material constituting the separation barrier itself.

Abstract: An allergic response indicator is provided which comprises a cutaneous three dimensional polymeric sheet capable of self-adherence to the epidermis of a subject and containing an indicator compound distributed throughout said cutaneous three dimensional polymeric sheet which, when applied to said epidermis, is released thereto over the period of application, whereby upon release of said indicator compound an allergic reaction is manifested by visual signs of skin irritation at the site of application upon the removal of said allergic response indicator.

Abstract: A noningestible separation barrier having one or more pores of micropores (of one or more diameters) therein, with the pores or micropores being initially plugged with one or more materials selected for its/their solubility and/or integrity characteristics relative to certain environmental conditions. Ordinarily, the pores or micropores of the noningestible separation barrier are initially filled with at least one material having greater erodibility, under a given environmental condition, than the material constituting the separation barrier itself. The combination of the release rate (if any) or other membrane characteristic of the separation barrier, combined with the release rate and/or erosion life of the plugged pores, enables complex separations including variable release of cells, colloids, solutes or solvents over time, such as when the plugged pores remain intact until erosion is triggered by an environmental change such as solvent addition or ionic conditions or pH or thermal change.

Abstract: A chlorhexidine complex is prepared by complexing chlorhexidine (a divalent, cationic antiseptic) with an anionic polymer such as algin or carboxymethylcellulose. The complex is insoluble but can be granulated or crushed to a fine powder. In powdered form the complex forms stable aqueous dispersions. The chlorhexidine complex is suitable for inclusion in oral hygiene compositions such as dentrifrices, and in other antibacterial compositions such as opthalmic under-eye-lid treatment capsules topical preparations and ocular solutions.

Abstract: Buccal dosage forms for transmucosal administration of drugs comprise a pharmaceutical compound dispersed in an erodible matrix comprisingfrom about 20 to about 75 percent by weight of a low molecular weight polyethylene glycol component,from about 2 to about 65 percent by weight of a medium or high molecular weight polyethylene glycol component,from about 1% to about 40% percent by weight of an auxiliary high molecular weight polymer.Preferred auxiliary high molecular weight polymers are polyethylene oxide and polyvinylpyrrolidone which improve the molding properties of the matrix and provide water-activated adhesive properties to the compositions to provide a buccal dosage form.

Abstract: A protective skin matrix is provided which is particularly suited for the protection of burned or wounded patients. The matrix may be either cured, applied in sheets, or painted or sprayed directly onto the burned or wounded patient. The protective skin matrix includes polyvinylpyrrolidone, polyvinylalcohol, and glycerol.

Abstract: A trinitroglycerol-containing substantially disaccharide-free polymeric diffusion matrix is provided for the transdermal systemic delivery of trinitroglycerol through the skin of a patient. The polymeric diffusion matrix contains sufficient trinitroglycerol to be released over a prolonged period of time and comprises a first lower molecular weight, partially hydrolyzed polyvinylalcohol component, a second higher molecular weight, essentially fully hydrolyzed polyvinylalcohol component, and glycerol.

Abstract: A protective skin matrix is provided which is particularly suited for the protection of burned or wounded patients. The matrix may be either cured, applied in sheets, or painted or sprayed directly onto the burned or wounded patient. The protective skin matrix includes polyvinylpyrrolidone, polyvinylalcohol, and glycerol.

Abstract: A self-supporting polymeric diffusion matrix provides for the sustained release of propranolol in order to deliver said propranolol to a patient. The matrix comprises from about 1 to about 60% by weight of a polar plasticizer, from about 5 to about 20% by weight polyvinylalcohol having a molecular weight from about 50,000 to about 150,000, from about 10 to about 25% by weight polyvinylalcohol having a molecular weight from about 4,000 to about 15,000, from about 2 to about 30% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of the propanolol to provide a sustained release of said propranolol over a prolonged period.

Abstract: There is disclosed a polymeric diffusion matrix for the sustained release of chlorpheniramine maleate by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of chlorpheniramine maleate.

Abstract: A polymeric diffusion matrix is provided comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol, from about 2 to about 10% water soluble polymer with hydration sites which in combination with the remaining ingredients yields a matrix capable of sustained release of a drug dispersed therein, and the balance water, the percentages being by weight.

Abstract: A polymeric diffusion matrix is provided comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol, from about 2 to about 10% water soluble polymer with hydration sites which in combination with the remaining ingredients yields a matrix capable of sustained release of a drug dispersed therein, and the balance water, the percentages being by weight.

Abstract: A self-supporting polymeric diffusion matrix provides for the sustained release of propranolol in order to deliver the propranolol to a patient. The matrix comprises from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight polyvinylalcohol, from about 2 to about 30% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of propranolol to provide a sustained release of propranolol over a prolonged period.

Abstract: This invention provides an aqueous mixture capable of being sprayed onto the leaves of plants and being cured in situ on the leaves. The thus cured mixture comprises polyvinylalcohol and polyvinylpyrrolidone. The cured mixture is capable of the sustained release of an active ingredient contained therein.

Abstract: A capsule for housing pellets is disclosed having two members, the first with a raised portion and the second with a connecting groove and an annular groove for interconnection with the raised portion to secure the two members together.

Abstract: A polymeric diffusion matrix for the sustained release, intravaginal administration of an estrogen is provided. The matrix consists of polyvinylalcohol, polyvinylpyrrolidone and a polar plasticizer.